Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence in the United States; European Union; Japan, and Rest of the world.


TSX:DHT.UN - Post by User

Comment by Marley66on Jul 05, 2023 2:00am
96 Views
Post# 35526773

RE:National bank

RE:National bank And....DRI has another deal in late-stage due diligence, which, should it close, will very likely result in a firm guidance of growing cash receipts.
Transaction Details
Details of the transaction include 1) upfront purchase price of US$85 mln; 2) DRI to receive a mid-single digit tiered royalty on worldwide sales (we are assuming U.S. and E.U. countries in our forecasts); 3) an undisclosed (but likely in the US$ millions) regulatory milestone payment following potential E.U. approval (decision in the NTM); 4) undisclosed (but likely in the US$ millions) milestone payment(s) should sales exceed certain thresholds; 5) 15 years of patent protection (until January 2038); 6) DRI to receive quarterly royalty payments on a one-quarter lag basis from April 1, 2023 (first payment in Q3/2023); and 7) the deal to be financed via a combination of cash and credit.
As discussed, we preliminarily estimate an IRR in the upper end of DRI’s guided 10%-14% target range.
<< Previous
Bullboard Posts
Next >>